全球临床试验申请监管协调与简化应加速疫苗临床开发与可及性
本文论述疫苗研发受各国监管要求差异影响而延迟,强调临床试验申请在化学制造与控制、非临床和临床方面的要求在不同国家和地区差异显著,增加研发复杂性并延误新型疫苗开发与公平可及。文章呼吁WHO等全球机构与各国监管机构合作建立并实施监管趋同与协调,以加速疫苗临床开发并更早获得救命疫苗。
要点
- 各国临床试验监管要求差异显著,增加疫苗研发复杂性并导致显著延迟。
- 监管趋同与协调不足将无法充分实现科学进步带来的益处。
- 亟需WHO与各国监管机构合作建立并实施监管协调。
核心结论
- 监管趋同与协调的进展不足将导致科学进步带来的益处无法充分实现。
- 全球机构如WHO亟需与各国监管机构合作建立并实施监管协调。
研究设计与样本
- 本文为论述性文章,未报告系统检索范围或样本量。
主要发现
- 临床试验的监管要求(包括化学制造与控制、非临床和临床)在不同国家和地区之间差异显著。
- 监管要求差异增加疫苗研发复杂性,并导致新型疫苗开发显著延迟,最终影响人群公平可及。
临床怎么用
- 疫苗开发者与制造商在跨国家或地区开展临床试验时需应对不同的监管要求。
- 全球机构与各国监管机构应合作推动监管趋同与协调并予以实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines continue to play a central role in our ability to prevent disease, save lives, and improve health. The scientific community, including our own researchers, are driven by a shared purpose to improve vaccine technologies and bring the benefits of immunization to everyone, regardless of where they live - as soon as possible, especially when the medical need is considerable. Vaccine developers and manufacturers (sometimes referred to as "study sponsors" or "applicants") are exploring technological advancements to translate breakthrough discoveries into novel vaccines which have the potential to provide protection from life-threatening and debilitating infectious diseases. Developing new vaccines is a lengthy process regulated by guidance provided by independent organizations, National Regulatory Authorities (NRAs) and the World Health Organization. As most infectious diseases can span a considerable area of the world, clinical trials are often conducted across different countries and regions. Regulatory requirements for clinical trials (both Chemistry Manufacturing & Controls - CMC, nonclinical and clinical) vary significantly between the different countries and regions adding to the complexity of vaccine development and leading to significant delays in the development of novel vaccines and ultimately equitable access for populations to these innovations. Without progress in terms of regulatory convergence and harmonization the benefits from these scientific advancements will not be fully realized. There is an urgent need by global bodies such as WHO to partner with and the NRAs to establish and implement.
引用
- Scheppler L, De Clercq N, McGoldrick M, et al. Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines. Vaccine. 2021. PMID: 33422378. doi:10.1016/j.vaccine.2020.11.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。